Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for rapidly treating severe hypoglycemia

a technology of severe hypoglycemia and rapid treatment, applied in the direction of peptide/protein ingredients, extracellular fluid disorder, metabolic disorder, etc., can solve the problems of imminent severe hypoglycemia or severe hypoglycemia

Active Publication Date: 2014-08-07
XERIS PHARMA
View PDF4 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new use for a composition that can be used to treat severe hypoglycemia in patients. The composition contains a glucagon peptide and an aprotic polar solvent, which is a non-volatile buffer. The glucagon peptide is dried in a non-volatile buffer and remains stable for several minutes. The composition can be administered to patients to maintain or raise their blood glucose levels quickly. This can prevent or treat hypoglycemia in patients who are unable to self-treat or who have a risk of developing hypoglycemia. The composition can be administered as a fast-acting treatment to patients with blood glucose levels below 70 mg / dL. The patent also provides a method for diagnosing hypoglycemia in patients based on the glucose monitoring device and trending downwards in blood glucose levels.

Problems solved by technology

Such patients either have severe hypoglycemia or are at risk of imminently developing severe hypoglycemia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for rapidly treating severe hypoglycemia
  • Methods for rapidly treating severe hypoglycemia
  • Methods for rapidly treating severe hypoglycemia

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Glucagon Solutions for Use in Freeze-Drying

[0120]Various solutions were prepared to contain glucagon at a concentration of 10 mg / mL. The solutions contained, alternatively, glycine, citrate or phosphate at 5 mM, generally providing a buffer establishing a pH of 3. The solution also contained a sugar, alone or in combination, in amounts equal to the w / v amount of glucagon (1:1) or at 200% (2:1) of the amount of glucagon. The sugars were trehalose, HES, and .beta.-cyclodextrin (β-CD). Some solutions also contained Tween-20 at 0.10% w / v as a surfactant. The various formulations were mixed to substantial homogeneity in amounts as described in Table 1 below.

TABLE 1Glucagon Mixtures for Subsequent LyophilizationGlycineCitratePhosphateGlucagonBufferBufferBufferTrehaloseHESβ-CDTween-20Formulation #(mg / ml)(mM)(mM)(mM)(mg / ml)(mg / ml)(mg / ml)(mg / ml)155000000255000000.01355001000045500010005550055006550000100750500000850500000.0195050100001050500100011505055001250500010013500500001...

example 2

Preparation of Dry Glucagon Powder by Freeze-Drying

[0122]The above formulations of Table 1 were pipetted (0.3 mL) into 3-mL lyophilization vials (13-mm ID). The formulations were lyophilized in a FTS Durastop freeze-drier (Stoneridge, N.Y.). Samples were frozen at −40° C. at a ramp of 2.5° C. / min and maintained for 2 hours (h) to allow sufficient freezing. The sample temperature was then increased to −5° C. at a ramp of 2° C. / min and held for 2 h as an annealing step. The temperature was then decreased to 30° C. at a ramp of 1.5° C. / min and the vacuum was turned on at 60 mTorr. The primary drying was set for 24 h. The temperature was gradually increased to 40° C. at a ramp of 0.5° C. / min and held for additional 10 h. After drying was complete, the vials were capped under vacuum using XX stoppers from the West Pharmaceutical company (product #10123524). None of the formulations showed any evidence of cake collapse following freeze-drying. The moisture content of the final dried produ...

example 3

Preparation of Glucagon Formulations in Aprotic Polar Solvents

[0123]Six of the dry powders made from the solutions in Table 1 were selected for formulation in polar, aprotic solvents: [0131] 1. Buffer (glycine)+trehalose (200% relative to glucagon) (formulation #3) [0132] 2. Buffer (glycine)+HES (200% relative to glucagon) (formulation #4) [0133] 3. Buffer (glycine)+trehalose (100% relative to glucagon)+HES (100% relative to glucagon) (formulation #5) [0134] 4. Buffer (glycine)+Tween-20 (0.01% w / v)+trehalose (200% relative to glucagon) (formulation #19) [0135] 5. Buffer (glycine)+Tween-20 (0.01% w / v)+HES (200% relative to glucagon) (formulation #20) [0136] 6. Buffer (glycine)+Tween-20 (0.01% w / v)+trehalose (100% relative to glucagon)+HES (100% relative to glucagon) (formulation #21)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a method for treating or preventing hypoglycemia in a patient comprising administering an effective amount of a composition comprising a glucagon peptide which has been dried in a non-volatile buffer, and wherein the glucagon peptide has a pH memory that is about equal to the pH of the glucagon peptide in the non-volatile buffer, and an aprotic polar solvent, wherein the moisture content of the formulation is less than 5%, and wherein the dried glucagon peptide maintains the pH memory that is about equal to the pH of the glucagon peptide in the non-volatile buffer when the dried glucagon peptide is reconstituted in the aprotic polar solvent, wherein the patient has been diagnosed as having a blood glucose level between 0 mg / dL and less than 50 mg / dL or has an indication of impending hypoglycemia based on a blood glucose monitoring device before administration of the composition, and wherein the patient has a blood glucose level greater than 50 mg / dL to 180 mg / dL within 1 to 20 minutes after administration of the composition.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 761,579, filed Feb. 6, 2013, the contents of which are incorporated by reference.BACKGROUND OF THE INVENTION[0002]I. Field of the Invention[0003]The present invention relates generally to pharmaceutical formulations and methods of using the same. More particularly, methods for rapidly treating moderate to severe hypoglycemia in emergency situations or preventing such situations from occurring.[0004]II. Description of the Related Art[0005]Recurrent episodes of severe hypoglycemia not only adversely impacts the quality of life for patients, but also, when severe, can cause seizures, coma, and even death. Severe hypoglycemia is defined as an episode of hypoglycemia that the patient cannot self-treat so that external help is required. Typically, neuroglycopenic symptoms and cognitive impairment begin at a blood glucose level of about 50 mg / dL (2.8 mmol / L), and include ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/26
CPCA61K38/26A61K9/0019A61K9/19A61P3/08
Inventor PRESTRELSKI, STEVEN J.NEWSWANGER, BRETT
Owner XERIS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com